Literature DB >> 22918864

Direct molecular typing of Bordetella pertussis from clinical specimens submitted for diagnostic quantitative (real-time) PCR.

David J Litt1, Elita Jauneikaite1, Draga Tchipeva2,1, Timothy G Harrison1, Norman K Fry1.   

Abstract

Molecular typing of Bordetella pertussis is routinely performed on bacterial isolates, but not on DNA extracted from nasopharyngeal aspirates or pernasal swabs submitted for diagnostic real-time PCR (qPCR). We investigated whether these DNA extracts were suitable for multilocus variable-number tandem repeat analysis (MLVA) and DNA sequence-based typing. We analysed all the available qPCR-positive samples received by our laboratory from patients <1 year of age between January 2008 and August 2010. Eighty-one per cent (106/131) of these generated a complete MLVA profile. This rose to 92 % (105/114) if only samples positive for both of the two targets used for the B. pertussis PCR (insertion element IS481 and pertussis toxin promoter ptxP) were analysed. Sequence-based typing of the pertactin, pertussis toxin S1 subunit and pertussis promoter regions (prn, ptxA and ptxP) was attempted on 89 of the DNA extracts that had generated a full MLVA profile. Eighty-three (93 %) of these produced complete sequences for all three targets. Comparison of molecular typing data from the 89 extracts with those from 111 contemporary bacterial isolates showed that the two sources yielded the same picture of the B. pertussis population [dominated by the MLVA-27 prn(2) ptxA(1) ptxP(3) clonal type]. There was no significant difference in MLVA type distribution or diversity between the two sample sets. This suggests that clinical extracts can be used in place of, or to complement, bacterial cultures for typing purposes (at least, in this age group). With small modifications to methodology, generating MLVA and sequence-based typing data from qPCR-positive clinical DNA extracts is likely to generate a complete dataset in the majority of samples from the <1 year age group. Its success with samples from older subjects remains to be seen. However, our data suggest that it is suitable for inclusion in molecular epidemiological studies of the B. pertussis population or as a tool in outbreak investigations.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22918864     DOI: 10.1099/jmm.0.049585-0

Source DB:  PubMed          Journal:  J Med Microbiol        ISSN: 0022-2615            Impact factor:   2.472


  5 in total

1.  Studying Bordetella pertussis populations by use of SNPeX, a simple high-throughput single nucleotide polymorphism typing method.

Authors:  Anne Zeddeman; Sandra Witteveen; Marieke J Bart; Marjolein van Gent; Han G J van der Heide; Kees J Heuvelman; Leo M Schouls; Frits R Mooi
Journal:  J Clin Microbiol       Date:  2015-01-07       Impact factor: 5.948

2.  Direct molecular typing of Bordetella pertussis from nasopharyngeal specimens in China in 2012-2013.

Authors:  Q Du; X Wang; Y Liu; Y Luan; J Zhang; Y Li; X Liu; C Ma; H Li; Z Wang; Q He
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-05-05       Impact factor: 3.267

3.  Survey and Rapid Detection of Bordetella pertussis in Clinical Samples Targeting the BP485 in China.

Authors:  Wei Liu; Yinghua Xu; Derong Dong; Huan Li; Xiangna Zhao; Lili Li; Ying Zhang; Xiao Wei; Xuesong Wang; Simo Huang; Ming Zeng; Liuyu Huang; Shumin Zhang; Jing Yuan
Journal:  Front Public Health       Date:  2015-03-05

4.  Rapid and simple SNP genotyping for Bordetella pertussis epidemic strain MT27 based on a multiplexed single-base extension assay.

Authors:  Kazunari Kamachi; Shu-Man Yao; Chuen-Sheue Chiang; Kentaro Koide; Nao Otsuka; Keigo Shibayama
Journal:  Sci Rep       Date:  2021-03-01       Impact factor: 4.379

5.  Molecular epidemiology of Bordetella pertussis in Greece, 2010-2015.

Authors:  Evangelia Petridou; Christel Barker Jensen; Athanasios Arvanitidis; Maria Giannaki-Psinaki; Athanasios Michos; Karen Angeliki Krogfelt; Randi Føns Petersen
Journal:  J Med Microbiol       Date:  2018-02-02       Impact factor: 2.472

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.